Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2013

01-10-2013 | Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events

Authors: George C. Roush, Venkata Buddharaju, Michael E. Ernst, Theodore R. Holford

Published in: Current Hypertension Reports | Issue 5/2013

Login to get access

Abstract

How chlorthalidone (CTDN) reduces risk for cardiovascular events (CVEs) can be considered in light of its ability to lower blood pressure (BP) and its non-BP related, pleiotropic effects. The mechanism by which CTDN lowers BP is unclear but may include alterations in whole body regulation and vasodilatory actions on vasculature, possibly mediated via its inhibitory effects on carbonic anhydrase. Additionally, CTDN has potentially beneficial, non-BP related, pleiotropic effects that include improvements in endothelial function, anti-platelet activity, and oxidative status. CTDN reduces pulse wave velocity, predictor of CVEs and a measure of central aortic stiffness associated with endothelial dysfunction. On the other hand, CTDN fosters hypokalemia, hyperglycemia, sympathetic discharge, and the renin–angiotensin–aldosterone system, but these potentially harmful effects do not appear to materially reduce CTDN’s ability to prevent CVEs. Further, CTDN reduces and regresses left ventricular hypertrophy (LVH), an important BP-dependent predictor of CVEs. Consistent with this finding, CTDN was more effective than amlodipine in reducing congestive heart failure (CHF) in the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attach Trial (ALLHAT). In reducing CVEs, CTDN was superior to lisinopril in ALLHAT and superior to hydrochlorthiazide in observational cohort analyses and in network analyses of randomized trials. A statistical synthesis of randomized trials suggests that the reduction in cardiovascular risk from CTDN can be explained primarily on the basis of its ability to lower blood pressure rather than its influence upon non-BP related, pleiotropic effects.
Literature
1.
Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zmmerli M. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12:375–82.PubMedCrossRef
2.
Collste P, Garle M, Rawlins MD, Sjogvist F. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses. Eur J Clin Pharmacol. 1976;9:319–25.PubMedCrossRef
3.
Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153–64.PubMedCrossRef
4.
Bengtsson C, Johnsson G, Sannerstedt R, Werkö L. Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. BMJ. 1975;1:197–9.PubMedCrossRef
5.
Neuvonen PJ, Pentikäinen PJ, Jounela AJ. Effect of diuretic, β-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol. 1978;6:363–7.PubMedCrossRef
6.
Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther. 1978;24(2):192–8.PubMed
7.
Tweeddale MG, Ogilvie RI, Ruedy J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther. 1977;22(5 Pt 1):519–27.PubMed
8.
Russell JG, Mayhew SR, Humphries IS. Chlorthalidone in mild hypertension—dose response relationship. Eur J Clin Pharmacol. 1981;20:407–11.PubMedCrossRef
9.
Morledge JH, Ettinger B, Aranda J, McBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebo-controlled, dose–response evaluation of chlorthalidone. J Am Geriatr Soc. 1986;34:199–206.PubMed
10.
•• Ernst ME, Goerdt CJ, Carter BL, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8. This trial shows that CTDN is superior to HCTZ in lowering nighttime BP, −13.5 versus −6.4, respectively.PubMedCrossRef
11.
Ernst ME, Carter BL, Zheng S, Grimm Jr RH. Meta-analysis of dose–response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440–6.PubMedCrossRef
12.
Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104–9.PubMedCrossRef
13.
• Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med 2012;125:1229.e1–1229.e10. This trial shows that CTDN lowers office and 24 h BP more than HCTZ with differences of −5.6 and −5.8, respectively.
14.
Tarzi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alterations in plasma volume and renin activity. Circulation. 1970;41:709–17.CrossRef
15.
Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation. 1959;20:1028–36.PubMedCrossRef
16.
Gifford Jr RW, Mattox VR, Orvis AL, Somes DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation. 1961;24:1197–205.PubMedCrossRef
17.
Roos JC, Boer P, Koomans HA, Sones DA, Rosevear JW. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol. 1981;19:107–12.PubMedCrossRef
18.
Tobian L. Why do thiazide diuretics lower blood pressure in essential hypertension? Annu Rev Pharmacol. 1967;7:399–408.PubMedCrossRef
19.
20.
Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin-Angiotensin-Aldosterone Syst. 2004;5:155–60.PubMedCrossRef
21.
Bagatin J, Pavlicevic I, Sardelic S, Pivac N, Rumboldt Z. Vascular effects of chlorthalidone in mild hypertensives. Int J Clin Pharmacol Res. 1995;15:201–8.PubMed
22.
Puscas I, Coltau M, Baican M, Domuta G, Hecht A. Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25:271–9.PubMed
23.
+Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: sulfonamide diuretics revisited—old leads for new applications? Org Biomol Chem. 2008;6:2499–506.PubMedCrossRef
24.
Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension. 2010;56:335–7.PubMedCrossRef
25.
Calder JA, Schachter M, Sever PS. Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmacol. 1994;24:158–64.PubMedCrossRef
26.
Pickkers P, Garcha RS, Schachter M, Smits P, Hughes AD. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension. 1999;33:1043–8.PubMedCrossRef
27.
Aamand R, Dalsgaard T, Jensen FB, Simosen U, Roepstorff A, Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol. 2009;297:H2068–74.PubMedCrossRef
28.
Yamanari H, Nakamura K, Miura D, Yamanari S, Ohe T. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. Clin Exp Hypertens. 2009;31(7):585–94.PubMedCrossRef
29.
Dell’Omo G, Penno G, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther. 2005;10(4):265–72.PubMedCrossRef
30.
Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010;56(3):463–70.PubMedCrossRef
31.
Vaitkevicius H, Turner I, Spalding A, Lockette W. Chloride increases adrenergic receptor-mediated platelet and vascular responses. Am J Hypertens. 2002;15(6):492–8.PubMedCrossRef
32.
Sato K, Dohi Y, Kojima M Takase H, Suzuki S, Ito S. Antioxidative effects of thiazide diuretics in refractory hypertensive patients. 2010;60(10):612–6.
33.
McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006;48(4):602–8. Epub 2006 Aug 28.PubMedCrossRef
34.
Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121(4):505–11.PubMedCrossRef
35.
Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013;36(1):79–84.PubMedCrossRef
36.
Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741–51.PubMedCrossRef
37.
•• Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–94. This head-to-head comparison of the 2 drugs in an observational cohort study shows a 21 % reduction in CVEs from CTDN versus HCTZ.PubMedCrossRef
38.
Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35(5):1025–30.PubMedCrossRef
39.
Kostis JB, Lacy CR, Hall WD, Wilson AC, Borhani NO, Krieger SD, et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. The SHEP Study Group. Am J Cardiol. 1994;74(5):464–7.PubMedCrossRef
40.
• Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59(5):926–33. This observational study concludes: “Thus, for most patients, concerns about potassium levels should not influence the clinician’s decision about initiating hypertension treatment with low-moderate doses of thiazide diuretics (12.5–25.0 mg of C [chlorthalidone])”.PubMedCrossRef
41.
Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9.PubMedCrossRef
42.
Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191–201.PubMedCrossRef
43.
Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcome. 2012;5(2):153–62.CrossRef
44.
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35.PubMedCrossRef
45.
Wright Jr JT, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169(9):832–42.PubMedCrossRef
46.
Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94(4):1361.PubMedCrossRef
47.
Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60(2):319–25.PubMedCrossRef
48.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105–12.CrossRef
49.
Ofili EO, Cohen JD, St Vrain JA, Pearson A, Martin TJ, Uy ND, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998;279:778–80.PubMedCrossRef
50.
• Ernst ME, Neaton JD, Grimm Jr RH, Collins G, Thomas W, Soliman EZ, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension. 2011;58:1001–7. CTDN reduces LVH in this observational study of the MRFIT trial.PubMedCrossRef
51.
Bacharova L, Estes H, Bang L, Rowlandson I, Schillaci G, Verdecchia P, et al. The first statement of the Working Group on Electrocardiographic Diagnosis of Left Ventricular Hypertrophy. J Electrocardiol. 2010;43:197–9.PubMedCrossRef
52.
Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am Heart J. 2005;150:161–7.PubMedCrossRef
53.
Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010;159:652–8.PubMedCrossRef
54.
• Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7. This network meta-analysis finds that CTDN reduces CVEs by 21 % more than HCTZ.PubMedCrossRef
55.
Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447–55.PubMedCrossRef
56.
Roush GC, Holford TR, Guddati AK. Comment. Chlorthalidone versus hydrochlorothiazide. Ann Intern Med. 2013;158:920.
57.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCrossRef
Metadata
Title
Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events
Authors
George C. Roush
Venkata Buddharaju
Michael E. Ernst
Theodore R. Holford
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 5/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0372-1

Other articles of this Issue 5/2013

Current Hypertension Reports 5/2013 Go to the issue

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Current Insights and New Perspectives on the Roles of Hyperglucagonemia in Non-Insulin–Dependent Type 2 Diabetes

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Hypertension after Kidney Transplantation: A Pathophysiologic Approach

Pediatric Hypertension (JT Flynn, Section Editor)

Determinants of Neonatal Blood Pressure

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Aldosterone Synthase Inhibition in Hypertension

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits